1. Volume 373, Issue 9658, Pages 125-136 (January 2009)
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study 
The Lancet 
Volume 373, Issue 9658, Pages (January 2009)
DOI: /S (08)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1 ASTEC trial design
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2 Profile of ASTEC surgical trial
We did not collect logs of patients assessed for eligibility. TAH=total abdominal hysterectomy. BSO=bilateral salpingo-oophorectomy. H=hysterectomy.
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Overall survival (A), disease and treatment-related deaths (B), and recurrence-free survival (C) by treatment group
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

5. Figure 4
Kaplan-Meier plots for the two treatment groups for overall and recurrence-free survival together with the model curves from fitting the Royston-Parmar parametric model
A and B show Kaplan-Meier estimates, with Royston-Parmar parametric model fitted. C and D show the absolute difference over time (95% CI) in survival from Royston-Parmar parametric model.
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

6. Figure 5
Effect of lymphadenectomy on overall survival (A) and recurrence-free survival (B) in women in different risk groups of recurrence
O–E=observed minus expected. Outer bars show 99% CI, inner bars show 95% CI.
The Lancet  , DOI: ( /S (08) )
Copyright © 2009 Elsevier Ltd Terms and Conditions